Q
Slow digestion, allowing users to feel fuller for longer
When GLP-1 Medications Are No Longer Working for You By Trace Curry, MD, FASMBS Over the last several years, GLP-1 medications such as semaglutide and tirzepatide have changed the conversation around obesity treatment
It creates a lot of demand, and it creates openings for people to exploit that demand, Jay tells TODAY.com
Emerging candidates in late-stage development include CagriSema (semaglutide combined with cagrilintide, an amylin analog), retatrutide (a triple agonist targeting GLP-1, GIP, and glucagon receptors), and orforglipron (a non-peptide oral GLP-1 agonist that does not require the fasting restrictions of Rybelsus)
Microdosing Standard therapeutic doses (semaglutide 1.02.4mg/week, tirzepatide 515mg/week) are designed for significant weight loss in people who do not train intensely